Integrin receptors – a therapeutic target for therapy resistant prostate carcinoma?
Laufzeit: 01.01.2018 - 31.12.2022
Kurzfassung
Evaluation of the impact of integrin α and β subtypes in prostate carcinoma cells resistant to taxane-based therapies and androgen signaling inhibitors.
